Supplementary Data — Amubarvimab/romlusevimab for COVID-19: real-time meta-analysis of 4 studies

@CovidAnalysis, October 2026, Version 4V4 (V1 2024)
c19early.org
October 2026

Amubarvimab COVID-19 outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Evering (DB RCT)91%0.09 · 0.01–0.70death1/39011/390ACTIV-2/A5401 Evering (DB RCT)−20%1.20 · 0.83–1.75PASC53/39044/390ACTIV-2/A5401 Evering (DB RCT)61%0.39 · 0.22–0.68hosp.16/39041/390ACTIV-2/A5401 Evering (DB RCT)67%0.33 · 0.19–0.56death/hosp.17/39052/390ACTIV-2/A5401 Self (DB RCT)−15%1.15 · 0.54–2.41death15/17613/178ACTIV-3/TICO Self (DB RCT)7%0.93 · 0.76–1.14no recov.21/17627/178ACTIV-3/TICO Self (DB RCT)0%1.00 · 0.68–1.47no recov.173 (n)178 (n)ACTIV-3/TICO Yalan−71%1.71 · 0.69–4.25death12/1707/170 Yalan−8%1.08 · 0.74–1.58ICU42/17039/170 Yalan8%0.92 · 0.87–0.97hosp. time170 (n)170 (n) Yalan7%0.93 · 0.89–0.98viral time170 (n)170 (n) Qu (ICU)46%0.54 · 0.29–1.04death47 (n)47 (n)ICU patients Qu (ICU)4%0.96 · 0.57–1.64viral+47 (n)47 (n)ICU patients
00.511.52+
Rotate screen for more detailsIncrease width for more details
← Amubarvimab/
romlusevimab
reduces riskAmubarvimab/
romlusevimab
increases risk →
Fig. S1. All outcomes.
Loading..
Fig. S2. Comparison of results for RCTs versus observational studies. For COVID-19 treatments, there is no significant difference between the results of RCTs and observational studies. Observational studies do not systematically over or underestimate efficacy. For high-cost treatments, there is a non-significant trend towards RCTs showing greater efficacy.